Docking also confirmed binding of designed derivatives with AChE. Hence novel derivatives with high binding energy and controlled reactivity were designed for retrosynthesis.Controlled release formulations are administered once a day and reduce frequency of dose and ensuring patient’s compliance. In the current research controlled release matrices…[Leer más]